A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder.

Trial Profile

A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Actual patient number is 29 as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Planned end date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top